Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
49 hedge funds and large institutions have $4.73M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 10 closing their positions.
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
52% less capital invested
Capital invested by funds: $9.77M → $4.73M (-$5.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$25.1M |
| 2 |
DPCM
Darlington Partners Capital Management
Greenbrae,
California
|
+$335K |
| 3 |
TCA
Taconic Capital Advisors
New York
|
+$104K |
| 4 |
SFM
Soros Fund Management
New York
|
+$50.7K |
| 5 |
SBLIC
Security Benefit Life Insurance Company
Topeka,
Kansas
|
+$41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$833K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$738K |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$257K |
| 4 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$172K |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$150K |
DNA.WS Hedge Fund Activity: Q2 2022 in Review
49 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q2 2022, worth a combined $4.73M — down 52% from $9.77M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DNA.WS positions and 10 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Guggenheim Capital, adding an estimated $25.1M. The largest seller was LMR Partners, exiting entirely with an estimated $833K sold.
- 49 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q2 2022, up from 47 in Q1 2022.
- Funds reported $4.73M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q2 2022, down 52% quarter-over-quarter.
- 12 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q2 2022 and 10 closed out, a net change of +2 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q2 2022 was Guggenheim Capital, an estimated $25.1M added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q2 2022 was LMR Partners, an estimated $833K sold.
Based on aggregated 13F filings for Q2 2022.